Amgen Inc BDR (AMGN34)

43.90 -0.01 (-0.02%)
Delayed Data BRL Disclaimer

Amgen Inc BDR Company Profile

Industry
Biotechnology
Sector
Healthcare
Employees
24300
Equity Type
DRC
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company’s products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Contact Information
Address
Thousand Oaks,91320-1799 United States
Phone
805 447 1000
Fax
805 447 1010
Top Executives
Name
Age
Since
Title
Robert A. Bradway 58 2007 Chairman, CEO & President
Ronald D. Sugar 73 2010 Independent Director
Tyler E. Jacks 61 2012 Independent Director
Amy E. Miles 55 2020 Independent Director
Ellen J. Kullman 66 2016 Independent Director
Brian J. Druker 66 2018 Independent Director
Wanda M. Austin 68 2017 Independent Director
R. Sanders Williams 73 2014 Independent Director
Greg C. Garland 65 2013 Independent Director
S. Omar Ishrak 66 2021 Independent Director
Robert A. Eckert 68 2012 Lead Independent Director
Judy L. Gawlik Brown 53 2017 Senior VP & Chair of the Amgen Foundation
Michael V. Drake 0 2022 Independent Director
Charles M. Holley 65 2017 Independent Director
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.